Cas:41270-80-8 methyl 2-formamidobenzoate manufacturer & supplier

Chemical Name:methyl 2-formamidobenzoate

CAS.NO:41270-80-8

Synonyms:Methyl-N-formyl-anthranilat;N-Formyl-anthranilsaeure-methylester;N-formylanthranilic acid methyl ester;methyl 2-(formylamino)benzoate;2-formylamino-benzoic acid methyl ester;Methyl N-formylanthranilate;Benzoic acid,2-(formylamino)-,methyl ester

Molecular Formula:C₉H₉NO₃

Molecular Weight:179.17300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:367.8ºC at 760 mmHg

Density:1.243g/cm3

Index of Refraction:1.578

PSA:58.89000

Exact Mass:179.05800

LogP:1.69100

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Methyl-N-formyl-anthranilat chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzoic acid,2-(formylamino)-,methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-formylanthranilic acid methyl ester Use and application,N-Formyl-anthranilsaeure-methylester technical grade,usp/ep/jp grade.

Related News: Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis. methyl 2-formamidobenzoate manufacturer Saudi Arabia��s state airline and Oman also suspended flights to China on Sunday in reaction to the coronavirus epidemic, according to Reuters. methyl 2-formamidobenzoate supplier Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). methyl 2-formamidobenzoate vendor Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). methyl 2-formamidobenzoate factory Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).